Neurocrine Biosciences INC Form 4 insider transactions

Director William H Rastetter contributed 14,250 shares of Neurocrine Biosciences (NBIX) common stock to an exchange fund on August 15, 2024.

Gary A. Lyons, a director of Neurocrine Biosciences, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences' CFO, Matt Abernethy, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Chief Regulatory Officer Ingrid Delaet of Neurocrine Biosciences reports the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, exercised stock options and sold shares according to a pre-arranged trading plan.

Julie Cooke, Chief Human Resources Officer at Neurocrine Biosciences, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences, executed stock transactions on August 1, 2024, involving the exercise of stock options and subsequent sale of shares.

Julie Cooke, Chief Human Resources Officer of Neurocrine Biosciences, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Director Gary Lyons exercised stock options and sold shares of Neurocrine Biosciences under a pre-arranged 10b5-1 trading plan.

Neurocrine Biosciences' Chief Financial Officer, Matt Abernethy, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Julie Cooke, Chief Human Resources Officer at Neurocrine Biosciences, exercised stock options and sold 10,000 shares of common stock at an average price of $140.1864 per share, according to a recent SEC filing.

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, exercised stock options and sold shares on July 1, 2024, according to a pre-arranged 10b5-1 trading plan.

Chief Regulatory Officer Ingrid Delaet of Neurocrine Biosciences reported the acquisition and disposition of company stock on May 31, 2024, according to a Form 4 filing.

Director Stephen Sherwin exercised stock options and sold Neurocrine Biosciences (NBIX) shares on May 29, 2024, according to a Form 4 filing with the SEC.

Director William H Rastetter of Neurocrine Biosciences acquired 2,869 Restricted Stock Units (RSUs) on May 22, 2024, which will vest on May 22, 2025.

Director Christine A Poon reports acquisition of stock options and restricted stock units in Neurocrine Biosciences.

Director Shalini Sharp reports acquisition of stock options and restricted stock units in Neurocrine Biosciences.

Director Stephen A. Sherwin reported the acquisition of 2,869 Restricted Stock Units (RSUs) of Neurocrine Biosciences Inc. on May 22, 2024, which will vest on May 22, 2025.

Director Richard F. Pops acquired 2,869 Restricted Stock Units (RSUs) of Neurocrine Biosciences, Inc. on May 22, 2024, which will vest on May 22, 2025.

Director George J. Morrow acquired 2,869 Restricted Stock Units (RSUs) of Neurocrine Biosciences Inc. on May 22, 2024, which will vest on May 22, 2025.

Director Gary A. Lyons acquired stock options and restricted stock units in Neurocrine Biosciences Inc. on May 22, 2024.

Director Leslie V. Norwalk reported the acquisition of Neurocrine Biosciences Restricted Stock Units and Non-Qualified Stock Options on May 22, 2024.

Director Johanna Mercier reports acquisition of stock options and restricted stock units in Neurocrine Biosciences.

Director Shalini Sharp exercised stock options and sold shares of Neurocrine Biosciences (NBIX) under a pre-arranged 10b5-1 trading plan.

Director Richard F. Pops of Neurocrine Biosciences reports the acquisition and disposition of common stock and restricted stock units on May 17, 2024.

Director George J. Morrow exercised stock options in Neurocrine Biosciences on May 17, 2024.

Director Leslie V. Norwalk of Neurocrine Biosciences sold 1,106 shares of common stock at an average price of $141.8173, while also acquiring 2,100 shares through the vesting of restricted stock units.

Director Gary A. Lyons exercised stock options and disposed of 2,100 shares of Neurocrine Biosciences common stock on May 17, 2024.